Routine first-line detection of breast cancer therapy-related cardiotoxicity by serial, fast and ultra-low-dose equilibrium radionuclide angiography.
breast cancer
cardiotoxicity
chemotherapy
equilibrium radionuclide angiography
ionizing radiations
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
08
07
2022
accepted:
28
09
2022
medline:
14
6
2023
pubmed:
27
10
2022
entrez:
26
10
2022
Statut:
ppublish
Résumé
This study assesses a first-line left ventricular ejection fraction (LVEF) monitoring provided by an ultra-low-dose equilibrium radionuclide angiography (ERNA) in breast cancer women treated with potentially cardiotoxic drugs and analyzes patient outcome based on the ERNA results. Breast cancer women treated with anthracyclines, followed or not by trastuzumab, were monitored using ERNA with a high-sensitivity CZT-camera. Calibrated LVEF measurements were obtained with an almost threefold reduction of radiation doses and 10-min recording times. During a mean 24 ± 6 months follow-up, 552 ERNAs with a mean effective dose of 2.3 ± 0.6 mSv were performed in 195 women, among whom 22 (11%) presented both ERNA criteria of cardiotoxicity (LVEF < 50% and > 10% drop from baseline; Tox + group), 35 (18%) only one criterion (Tox ± group), and 138 (71%) neither (Tox - group). This ERNA-based classification correlated with trastuzumab-anthracycline treatment (p = 0.001), prior cardiovascular disease (p = 0.018), and cardiac outcome, with a 30-month survival with no cardiotoxicity-driven drug regimen changes of 97 ± 2% in Tox -, 60 ± 13% in Tox ± and 36 ± 13% in Tox + (p < 0.001) groups. First-line detection of breast cancer therapy-related cardiotoxicity by ultra-low-dose ERNA provides consistent results, confirming the excellent cardiac outcome for the greatest majority of women with no ERNA cardiotoxicity criteria.
Sections du résumé
BACKGROUND
This study assesses a first-line left ventricular ejection fraction (LVEF) monitoring provided by an ultra-low-dose equilibrium radionuclide angiography (ERNA) in breast cancer women treated with potentially cardiotoxic drugs and analyzes patient outcome based on the ERNA results.
METHODS
Breast cancer women treated with anthracyclines, followed or not by trastuzumab, were monitored using ERNA with a high-sensitivity CZT-camera. Calibrated LVEF measurements were obtained with an almost threefold reduction of radiation doses and 10-min recording times.
RESULTS
During a mean 24 ± 6 months follow-up, 552 ERNAs with a mean effective dose of 2.3 ± 0.6 mSv were performed in 195 women, among whom 22 (11%) presented both ERNA criteria of cardiotoxicity (LVEF < 50% and > 10% drop from baseline; Tox + group), 35 (18%) only one criterion (Tox ± group), and 138 (71%) neither (Tox - group). This ERNA-based classification correlated with trastuzumab-anthracycline treatment (p = 0.001), prior cardiovascular disease (p = 0.018), and cardiac outcome, with a 30-month survival with no cardiotoxicity-driven drug regimen changes of 97 ± 2% in Tox -, 60 ± 13% in Tox ± and 36 ± 13% in Tox + (p < 0.001) groups.
CONCLUSION
First-line detection of breast cancer therapy-related cardiotoxicity by ultra-low-dose ERNA provides consistent results, confirming the excellent cardiac outcome for the greatest majority of women with no ERNA cardiotoxicity criteria.
Identifiants
pubmed: 36289164
doi: 10.1007/s12350-022-03124-z
pii: 10.1007/s12350-022-03124-z
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Antibiotics, Antineoplastic
0
Anthracyclines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1202-1209Informations de copyright
© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Références
Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 2009;53:2201‐29.
doi: 10.1016/j.jacc.2009.02.013
pubmed: 19497454
Imbert L, Marie P-Y. Low-dose gated bloodpool SPECT: is it time to make the shift? J Nucl Cardiol 2021;28:951‐4.
doi: 10.1007/s12350-019-01872-z
pubmed: 31468378
Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, et al. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat 2019;176:261‐70.
doi: 10.1007/s10549-019-05178-z
pubmed: 31020471
Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the E European Association of Cardiovascular Imaging (EACVI) and the CARDIO-ONCOLOGY Council of the E European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504‐24.
doi: 10.1002/ejhf.1957
pubmed: 32621569
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911‐39.
doi: 10.1016/j.echo.2014.07.012
pubmed: 25172399
van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996;77:843‐50.
doi: 10.1016/S0002-9149(97)89179-5
pubmed: 8623737
Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008;35:851‐85.
doi: 10.1007/s00259-007-0694-9
pubmed: 18224320
Imbert L, Marie P-Y. CZT cameras: a technological jump for myocardial perfusion SPECT. J Nucl Cardiol 2016;23:894‐6.
doi: 10.1007/s12350-015-0216-2
pubmed: 26108415
Perrin M, Djaballah W, Moulin F, Claudin M, Veran N, Imbert L, et al. Stress-first protocol for myocardial perfusion SPECT imaging with semiconductor cameras: high diagnostic performances with significant reduction in patient radiation doses. Eur J Nucl Med Mol Imaging 2015;42:1004‐11.
doi: 10.1007/s00259-015-3016-7
pubmed: 25711177
Chawki MB, Goncalves T, Boursier C, Bordonne M, Verger A, Imbert L, et al. Assessment of the routine reporting of very low-dose exercise-first myocardial perfusion SPECT from a large-scale real-world cohort and correlation with the subsequent reporting of coronary stenosis at angiography. Eur J Nucl Med Mol Imaging 2022;49:1223‐31.
doi: 10.1007/s00259-021-05575-x
pubmed: 34655307
Tissot H, Roch V, Morel O, Veran N, Perrin M, Claudin M, et al. Left ventricular ejection fraction determined with the simulation of a very low-dose CZT-SPECT protocol and an additional count-calibration on planar radionuclide angiographic data. J Nucl Cardiol 2019;26:1539‐49.
doi: 10.1007/s12350-019-01619-w
pubmed: 30815836
Marie P-Y, Imbert L. Proposed volume-based methods for correcting the shift in left ventricular ejection fraction from blood-pool gated SPECT. J Nucl Cardiol 2019;26:1552‐4.
doi: 10.1007/s12350-019-01657-4
pubmed: 30784000
Liu Y-H, Fazzone-Chettiar R, Sandoval V, Tsatkin V, Miller EJ, Sinusas AJ. New approach for quantification of left ventricular function from low-dose gated bloodpool SPECT: validation and comparison with conventional methods in patients. J Nucl Cardiol 2021;28:939‐50.
doi: 10.1007/s12350-019-01823-8
pubmed: 31338796
Bailly M, Le Rouzic G, Metrard G. Gated tomographic radionuclide angiography using CZT gamma camera in patients receiving cardiotoxic chemotherapy: going faster and less irradiating. Clin Nucl Med 2019;44:472‐4.
doi: 10.1097/RLU.0000000000002569
pubmed: 30985432
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768‐801.
doi: 10.1093/eurheartj/ehw211
pubmed: 27567406
Elghazawy H, Venkatesulu BP, Verma V, Pushparaji B, Monlezun DJ, Marmagkiolis K, et al. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving anthracyclines ± trastuzumab: a meta-analysis of clinical studies. Crit Rev Oncol Hematol 2020;153:103006.
doi: 10.1016/j.critrevonc.2020.103006
pubmed: 32777728
Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol 2021;7:1544.
doi: 10.1001/jamaoncol.2021.3395
pubmed: 34436523
Cousins C, Miller DL, Bernardi G, Rehani MM, Schofield P, Vañó E, et al. ICRP publication 120: radiological protection in cardiology. Ann ICRP 2013;42:1‐125.
doi: 10.1016/j.icrp.2012.09.001
pubmed: 23141687
Chen DH, Tyebally S, Malloupas M, Roylance R, Spurrell E, Raja F, et al. Cardiovascular disease amongst women treated for breast cancer: traditional cytotoxic chemotherapy, targeted therapy, and radiation therapy. Curr Cardiol Rep 2021;23:16.
doi: 10.1007/s11886-021-01446-x
pubmed: 33501515
Banke A, Fosbøl EL, Ewertz M, Videbæk L, Dahl JS, Poulsen MK, et al. Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 2019;7:217‐24.
doi: 10.1016/j.jchf.2018.09.001
pubmed: 30819377
Florescu D-R, Nistor D-E. Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. Discoveries 2019;7:e89.
doi: 10.15190/d.2019.2
pubmed: 32309607
pmcid: 7093073
Koroleva I, Kopp MV, Kasulin AN, Kucheryavyy JA, Byakhov MJ. Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy. J Clin Oncol 2011;29:e11582.
doi: 10.1200/jco.2011.29.15_suppl.e11582
Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 2012;30:3792‐9.
doi: 10.1200/JCO.2011.40.0010
pubmed: 22987084
pmcid: 3478574
Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820‐6.
doi: 10.1200/JCO.2005.13.300
pubmed: 16258084
Collier P, Hussain M, Popovic ZB, Griffin BP. Cardiac surveillance for anti-HER2 chemotherapy. Cleve Clin J Med 2021;88:110‐6.
doi: 10.3949/ccjm.88a.19150
pubmed: 33526465
Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 2021;188:21‐36.
doi: 10.1007/s10549-021-06280-x
pubmed: 34115243
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep 2021;23:128.
doi: 10.1007/s11912-021-01114-x
pubmed: 34453232
pmcid: 8395382